紫杉烷联合铂类双药同期放化疗治疗局部晚期鼻咽癌的长期生存:一项回顾性研究
该回顾性研究纳入2013年1月至2018年12月在本中心接受紫杉烷联合铂类双药同期放化疗的104例局部晚期鼻咽癌患者,其中18例仅接受同期放化疗、86例接受同期放化疗联合辅助化疗。双药同期化疗的3年无进展生存率、总生存率、局部区域无复发生存率和无远处转移生存率分别为85.9%、96.0%、96.0%和90.8%,III期优于IVa期;3-4级急性化疗不良事件发生率为18.3%。作者认为该方案改善了长期生存,尤其局部控制率,并需进一步前瞻性评估。
要点
- 104例局部晚期鼻咽癌接受紫杉烷联合铂类双药同期放化疗,3年总生存率96.0%。
- III期 vs IVa期的3年无进展生存率分别为97.8% vs 75.5%(P=0.000)。
- 3-4级急性化疗不良事件发生率18.3%,最常见为白细胞减少(9.6%)。
核心结论
- 作者认为紫杉烷联合铂类双药同期放化疗改善了局部晚期鼻咽癌患者的长期生存,尤其是局部控制率,并需进一步前瞻性评估。
研究设计与样本
- 回顾性研究,纳入2013年1月至2018年12月在本中心接受紫杉烷联合铂类同期放化疗的104例局部晚期鼻咽癌患者。
- 104例中18例仅接受同期放化疗,86例接受同期放化疗联合辅助化疗。
- 采用Kaplan-Meier法(SPSS 23.0)进行统计分析,不同组间比较采用Wilcoxon秩和检验。
主要发现
- 无进展生存的中位随访时间为53.0个月(IQR 48.5-57.5)。
- 双药同期化疗的3年无进展生存率、总生存率、局部区域无复发生存率和无远处转移生存率分别为85.9%、96.0%、96.0%和90.8%。
- III期 vs IVa期的3年无进展生存率分别为97.8% vs 75.5%(P=0.000),总生存率分别为100% vs 92.5%(P=0.004),局部区域无复发生存率分别为100% vs 92.4%(P=0.015),无远处转移生存率分别为97.8% vs 82.8%(P=0.002)。
- 同期化疗期间3级或4级急性化疗不良事件发生率仅为18.3%。
- 最常见的急性化疗不良事件为白细胞减少(10例[9.6%]),其次为中性粒细胞减少(8例[7.6%])。
局限性
- 原文未报告局限性。
- 作者在结论中提出需进一步前瞻性评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study introduces innovative strategies, the doublet regimen of concurrent chemoradiotherapy, to ensure longer survival for locoregionally advanced nasopharyngeal carcinoma. METHODS: We retrospectively reviewed 104 locoregionally advanced nasopharyngeal carcinoma patients who underwent taxane combined platinum-based concurrent chemoradiotherapy in our center between January 2013 and December 2018. All statistical analyses were performed using the Kaplan-Meier method (SPSS 23.0). Different groups were compared with the Wilcoxon rank-sum test. RESULTS: Ultimately, 104 patients were selected for this study, including 18 and 86 who received either concurrent chemoradiation therapy alone or concurrent chemoradiation therapy plus adjuvant chemotherapy, respectively. The median follow-up time for progression free survival was 53.0 months (IQR 48.5-57.5). The 3-years progression-free survival (PFS), overall survival (OS), local-regional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS) rates of the doublet regimen of concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma were 85.9%, 96.0%, 96.0% and 90.8%, respectively. Additionally, we analyzed the subgroups and found that the 3-years PFS, OS, LRRFS and DMFS rates for stage III versus stage IVa were 97.8% versus 75.5% (P = 0.000), 100% versus 92.5% (P = 0.004), 100% versus 92.4% (P = 0.015) and 97.8% versus 82.8% (P = 0.002), respectively. During concurrent chemotherapy, acute chemotherapy adverse events of grade 3 or 4 was only 18.3%. Leukopenia was the most common acute chemotherapy adverse event (in 10 patients [9.6%]), followed by neutropenia (in 8 patients [7.6%]). CONCLUSION: The doublet regimen of taxane plus platinum concurrent chemoradiotherapy resulted in improved long-term survival of locoregionally advanced nasopharyngeal carcinoma patients, especially for local control rate and warrants further prospective evaluation.
引用
- Wang ZQ, Feng XD, Ge CL, et al. The long-term survival of the doublet regimen of concurrent chemoradiation therapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective study. Radiat Oncol. 2022. PMID: 36397078. doi:10.1186/s13014-022-02158-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。